• SOMATOM go.Sim and SOMATOM go.Open Pro help customers meet challenges in RT treatment planning
The U.S. Food and Drug Administration (FDA) has cleared the SOMATOM go.Sim and SOMATOM go.Open Pro – two computed tomography (CT) systems from Siemens Healthineers that are dedicated for radiation therapy (RT) planning.
The 64-slice SOMATOM go.Sim and 128-slice SOMATOM go.Open Pro are members of the SOMATOM go. platform, which was created to limit potential errors in radiation therapy planning and reduce time to treatment. The platform integrates hardware and software components such as patient marking lasers and automated quality assurance to simplify the treatment planning process, while the 85 cm bore accommodates positioning accessories and improves patient comfort. An innovative mobile workflow walks the radiation therapist through the setup process while the therapist remains with the patient to reduce anxiety.
Since 75 percent of respiratory patients breathe irregularly, motion artifacts often appear in 4D image sets.¹ The Direct Intelligent 4D (Direct i4D) technology of the SOMATOM go.Open Pro adapts image acquisition to patient breathing in real time to reduce those artifacts. Reducing unwarranted variations in the images can potentially decrease target margins, thereby sparing healthy tissue.
“With the FDA clearance of the SOMATOM go.Sim and SOMATOM go.Open Pro, Siemens Healthineers offers our customers revolutionary technology for radiation therapy planning,” said Hanno Dotzel, Vice President of Surgery and Cancer Therapy in the Advanced Therapies business at Siemens Healthineers North America. “The new i4D technology can help our customers dramatically reduce image artifacts, enabling them to reach a new level of precision in radiation therapy treatment planning.”
¹ Werner, R., Hofmann, C., Mücke, E., & Gauer, T. (2017). Reduction of breathing irregularity-related motion artifacts in low-pitch spiral 4D CT by optimized projection binning. Radiation Oncology, 12:100. https://ro-journal.biomedcentral.com/articles/10.1186/s13014-017-0835-7
For further information on the SOMATOM go.Sim and SOMATOM go.Open Pro, please see
www.siemens-healthineers.us/rt-go-platform
Contact for journalists
Jeff Bell
Phone: +484 868-8346; E-mail: jeffrey.t.bell@siemens-healthineers.com
Siemens Healthineers AG (listed in Frankfurt, Germany, DE:SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2019, which ended on September 30, 2019, Siemens Healthineers, which has approximately 52,000 employees worldwide, generated revenue of €14.5 billion and adjusted profit of €2.5 billion.
Further information is available at www.siemens-healthineers.com.
